Effectiveness and Safety of Autologous Virus-Specific T-Cell Therapy for Persistent COVID-19 in People With Immunocompromise: A Clinical Trial Study

Raeseok Lee; Nayoun Kim; Won Bok Kim; Keon Il Im; Dukhee Nho; Sung Yeon Cho; Chulmin Park; Kyongmin Sarah Beck; Gyeong Hui Lee; Inkee Lee; Seok Goo Cho; Dong Gun Lee

doi:10.1093/cid/ciaf302

Effectiveness and Safety of Autologous Virus-Specific T-Cell Therapy for Persistent COVID-19 in People With Immunocompromise: A Clinical Trial Study

Raeseok Lee
, Nayoun Kim
, Won Bok Kim
, Keon Il Im
, Dukhee Nho
, Sung Yeon Cho
, Chulmin Park
, Kyongmin Sarah Beck
, Gyeong Hui Lee
, Inkee Lee
, Seok Goo Cho
, Dong Gun Lee

Department of Internal Medicine

Ltd.
The Catholic University of Korea, College of Medicine

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

In this prospective study (N = 12), autologous virus-specific T cells (auto-VSTs) were successfully manufactured in 10 patients (83.3%). Three received VSTs, achieving viral clearance and symptom resolution without severe adverse events. Auto-VST therapy appears feasible and effective for managing persistent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection; however, manufacturing and timing challenges remain.

Original language	English
Pages (from-to)	e510-e514
Journal	Clinical Infectious Diseases
Volume	81
Issue number	6
DOIs	https://doi.org/10.1093/cid/ciaf302
State	Published - 15 Dec 2026

Bibliographical note

Publisher Copyright:
© 2025 The Author(s).

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

COVID-19
SARS-CoV-2
T-lymphocytes, cytotoxic
adoptive transfer
immunocompromised host

Access to Document

10.1093/cid/ciaf302

Cite this

Lee, R., Kim, N., Kim, W. B., Im, K. I., Nho, D., Cho, S. Y., Park, C., Beck, K. S., Lee, G. H., Lee, I., Cho, S. G., & Lee, D. G. (2026). Effectiveness and Safety of Autologous Virus-Specific T-Cell Therapy for Persistent COVID-19 in People With Immunocompromise: A Clinical Trial Study. Clinical Infectious Diseases, 81(6), e510-e514. https://doi.org/10.1093/cid/ciaf302

@article{dbff5e2d044949b7822ac7fde0473360,

title = "Effectiveness and Safety of Autologous Virus-Specific T-Cell Therapy for Persistent COVID-19 in People With Immunocompromise: A Clinical Trial Study",

abstract = "In this prospective study (N = 12), autologous virus-specific T cells (auto-VSTs) were successfully manufactured in 10 patients (83.3\%). Three received VSTs, achieving viral clearance and symptom resolution without severe adverse events. Auto-VST therapy appears feasible and effective for managing persistent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection; however, manufacturing and timing challenges remain.",

keywords = "COVID-19, SARS-CoV-2, T-lymphocytes, cytotoxic, adoptive transfer, immunocompromised host",

author = "Raeseok Lee and Nayoun Kim and Kim, \{Won Bok\} and Im, \{Keon Il\} and Dukhee Nho and Cho, \{Sung Yeon\} and Chulmin Park and Beck, \{Kyongmin Sarah\} and Lee, \{Gyeong Hui\} and Inkee Lee and Cho, \{Seok Goo\} and Lee, \{Dong Gun\}",

note = "Publisher Copyright: {\textcopyright} 2025 The Author(s).",

year = "2026",

month = dec,

day = "15",

doi = "10.1093/cid/ciaf302",

language = "English",

volume = "81",

pages = "e510--e514",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

publisher = "Oxford University Press",

number = "6",

}

TY - JOUR

T1 - Effectiveness and Safety of Autologous Virus-Specific T-Cell Therapy for Persistent COVID-19 in People With Immunocompromise

T2 - A Clinical Trial Study

AU - Lee, Raeseok

AU - Kim, Nayoun

AU - Kim, Won Bok

AU - Im, Keon Il

AU - Nho, Dukhee

AU - Cho, Sung Yeon

AU - Park, Chulmin

AU - Beck, Kyongmin Sarah

AU - Lee, Gyeong Hui

AU - Lee, Inkee

AU - Cho, Seok Goo

AU - Lee, Dong Gun

PY - 2026/12/15

Y1 - 2026/12/15

N2 - In this prospective study (N = 12), autologous virus-specific T cells (auto-VSTs) were successfully manufactured in 10 patients (83.3%). Three received VSTs, achieving viral clearance and symptom resolution without severe adverse events. Auto-VST therapy appears feasible and effective for managing persistent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection; however, manufacturing and timing challenges remain.

AB - In this prospective study (N = 12), autologous virus-specific T cells (auto-VSTs) were successfully manufactured in 10 patients (83.3%). Three received VSTs, achieving viral clearance and symptom resolution without severe adverse events. Auto-VST therapy appears feasible and effective for managing persistent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection; however, manufacturing and timing challenges remain.

KW - COVID-19

KW - SARS-CoV-2

KW - T-lymphocytes, cytotoxic

KW - adoptive transfer

KW - immunocompromised host

UR - https://www.scopus.com/pages/publications/105029292080

U2 - 10.1093/cid/ciaf302

DO - 10.1093/cid/ciaf302

M3 - Article

C2 - 40493744

AN - SCOPUS:105029292080

SN - 1058-4838

VL - 81

SP - e510-e514

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

IS - 6

ER -

Effectiveness and Safety of Autologous Virus-Specific T-Cell Therapy for Persistent COVID-19 in People With Immunocompromise: A Clinical Trial Study

Abstract

Bibliographical note

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this